Ligand Pharma (LGND) PT Raised to $237 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Ligand Pharma (LGND) Tops Q4 EPS by 8c
February 6, 2020 4:05 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.71, $0.08 better than the analyst estimate of $0.63. Revenue for the quarter came in at $27 million versus the consensus estimate of $25.2 million.
Ligand made tremendous progress during 2019 in areas that will drive our future success, including new license agreements, outstanding revenue performance driven by record revenue for Captisol and Kyprolis royalties, expansion of our proprietary technology platforms and continued investment in internal programs, said John Higgins,... More
